- « Previous
- Clinical Pharmacology
- Next »
Hyalgan
Clinical Pharmacology
Clinical Pharmacology
Hyalgan
| Week | ||||||||
| 3 | 4 | 5 | 9 | 12 | 16 | 21 | 26 | |
Adjusted Means Hyalgan® |
27.23 | 21.54 | 19.29 | 20.04 | 20.26 | 20.83 | 18.44 | 17.88 |
Placebo |
32.35 | 28.57 | 25.67 | 24.28 | 26.66 | 25.44 | 24.77 | 26.73 |
Hyalgan® versus Placebo |
5.13 | 7.03 | 6.39 | 4.24 | 6.40 | 4.61 | 6.33 | 8.846 |
p-value |
0.06 | 0.01 | 0.01 | 0.1 | 0.03 | 0.1 | 0.02 | 0.004 |
| NUMBER (%) OF SUBJECTS IN CATEGORY | ||||||
| Hyalgan® | Placebo | TABLE 7 Subjects' Categorical Assessments of Pain for Completed Subjects in Prior 48 Hours: Level of Pain by Treatment Group at Baseline and Week 26Naproxen | ||||
| Baseline | Week 26 | Baseline | Week 26 | Baseline | Week 26 | |
None (0) |
0 (0.0) | 27 (25.7) | 0 (0.0) | 15 (13.0) | 0 (0.0) | 17 (15.0) |
Slight (1) |
1 (1.0) | 23 (21.9) | 0 (0.0) | 27 (23.5) | 0 (0.0) | 32 (28.3) |
Mild (2) |
2 (1.9) | 24 (22.9) | 2 (1.7) | 29 (25.2) | 2 (1.8) | 27 (23.9) |
Moderate (3) |
69 (65.7) | 26 (24.8) | 85 (73.9) | 34 (29.6) | 79 (70.5) | 28 (24.8) |
Marked (4) |
33 (31.4) | 5 (4.8) | 28 (24.3) | 10 (8.7) | 31 (27.7) | 9 (8.0) |
TOTAL |
105 (100) | 105 (100) | 115 (100) | 115 (100) | 112 * (100) | 113 (100) |
| * One Naproxen treated subject was missing a Baseline assessment. | ||||||
Brand Name: Hyalgan
Generic Name: Hyaluronate
Generic Name: Hyaluronate
- « Previous
- Clinical Pharmacology
- Next »
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Arthritis
Get the latest treatment options
WebMD Resources
Knee Cartilage Restoration
Advances in technology are helping painful old knees work like new again. See more WebMD Videos »
